Azathioprine-related myelosuppression in a patient homozygous for TPMT*3A

Nat Rev Nephrol. 2011 Jun 28;7(8):478-84. doi: 10.1038/nrneph.2011.74.

Abstract

Background: A 50-year-old man who had received a simultaneous pancreas and kidney transplant 9 years earlier developed pancytopenia 3 weeks after starting azathioprine therapy to treat worsening proteinuria suspected to be caused by sirolimus.

Investigations: Laboratory tests, including complete blood counts, measurement of serum levels of vitamin B(12) and folate, liver function tests, virological assays, and thiopurine S-methyltransferase (TPMT) genotyping.

Diagnosis: Severe myelosuppression as a consequence of azathioprine therapy in a patient homozygous for the TPMT*3A allele.

Management: Discontinuation of azathioprine, treatment with an erythropoiesis-stimulating agent, red blood cell transfusions, filgrastim (a granulocyte colony-stimulating factor analogue) and folic acid.

Publication types

  • Case Reports

MeSH terms

  • Azathioprine / adverse effects*
  • Erythrocyte Transfusion
  • Filgrastim
  • Folic Acid / therapeutic use
  • Genotype
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Homozygote
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Kidney Function Tests
  • Kidney Transplantation
  • Liver Function Tests
  • Male
  • Methyltransferases / genetics*
  • Middle Aged
  • Pancreas Transplantation
  • Pancytopenia / chemically induced*
  • Pancytopenia / therapy
  • Recombinant Proteins / therapeutic use

Substances

  • Immunosuppressive Agents
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Folic Acid
  • Methyltransferases
  • thiopurine methyltransferase
  • Azathioprine
  • Filgrastim